ORPHAN DRUGS MARKET Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2017–2025 © Coherent market Insights. All Rights Reserved REPORT DESCRIPTION Orphan Drugs Market Overview The drugs which are developed for treatment of rare diseases and conditions are referred to as orphan drugs. The rare diseases such as Tourette syndrome, Huntington’s disease, muscular dystrophy, myoclonus, and ALS (Lou Gehrig’s disease) are some of those diseases for treatment of which adequate drugs have not been developed, and hence these diseases are treated by orphan drugs. Orphan drugs are developed by the pharmaceutical companies for public health need, and the sales generated by this drugs are very minimal when compared to normal drugs. The orphan diseases manifest in patient populations representing 6-8% of the global population. Symptoms of some orphan diseases may appear at birth or in childhood including cystic fibrosis, infantile spinal muscular atrophy, familial adenomatous polyposis (FAP), and some others. Request to download and view Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/500 Developing novel indications for designated orphan drugs is expected to drive the orphan drugs market There are around 5,000 rare diseases listed globally and 80% of those are to genetic origins. The probability of getting infected by these diseases in adults is 50%.The need for the development of orphan drugs which will treat such diseases and proactive initiatives undertaken by government and regulatory authorities are the major factors driving the orphan drugs market. For instance, the authorities of U.S. FDA for orphan drug development department are providing the incentives to healthcare and biotechnology industries in order to enhance their research and development in orphan drugs. There are few drugs that have been withdrawn from the market due to certain risk developed over prolong administration of these drugs. © Coherent market Insights. All Rights Reserved REPORT DESCRIPTION The increasing prevalence of rare cancer in patients owing to oncological diseases segment to dominate in the orphan drugs market The global orphan drugs market is segmented on the basis of disease, by product type and by region On the basis of disease type, • Hematologic and Immunologic diseases • Infectious diseases • Metabolic diseases • Neurologic diseases • Oncologic diseases • Other orphan diseases On the basis of product type, • Biological orphan drugs • Non-biological orphan drugs Request a Customization: https://www.coherentmarketinsights.com/insight/request-customization/500 © Coherent market Insights. All Rights Reserved REPORT DESCRIPTION Numerous collaborative research programs across North America and Europe is owing to growth of orphan drugs market Regional segmentation of orphan drugs market by Coherent Market Insights comprises of North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America dominates the market globally due to factors such as established regulatory and reimbursement framework and incentives given by U.S. Food and Drug Administration (FDA) for research and development in orphan drugs sector. The various collaborative research programs across United States and Europe provides research data on rare diseases to manufacturers, patients and health experts which gives timely medical care, thus boost the orphan drug market. Whereas the prevalence of genetic diseases and growth of population are some factors which might allow the orphan drugs manufacturers to invest in the Asia Pacific region. Get Exclusive Discount on this CMI Report: https://www.coherentmarketinsights.com/insight/request-discount/500 Initiatives taken by government to increase the investment in orphan drugs development driving the growth of orphan drugs market. Key players operating the orphan drugs market are Acorda Therapeutics, Actelion Pharmaceuticals Ltd., Amgen, Alexion Pharmaceuticals, Baxter international, Bayer healthcare pharmaceuticals, Biomarin Pharmaceuticals, Novartis, F.Hoffmann-La Roche AG, Johnson and Johnson and many others. The increase in investments, and some initiatives taken by government helping the orphan drug manufacturers. For instance, U.S. government provides 50% of tax credit on the research and development expenses spent on the orphan drugs development by manufacturers. However the high cost of the orphan drugs and generation of small sales from it is amongst those factors which is lowering the interest of companies for market. © Coherent market Insights. All Rights Reserved ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES INDUSTRY ANALYSIS CUSTOMIZED RESEARCH SYNDICATED RESEARCH MARKET INTELLIGENCE SERVICES CONSULT STUDIES COUNTRY SPECIFIC STUDIES © Coherent market Insights. All Rights Reserved ABOUT CMI SECTOR COVERAGE BIOTECHNOLOGY CLINICAL DIAGNOSTIC HEALTHCARE IT MEDICAL DEVICES MEDICAL IMAGING PHARMACEUTICAL OUR CLIENTS Global Leading Equipment and System Manufacturers Marketing Consultancies and the Advertising Industry Component Providers and System Integrators Private and Government organization Distributors, Retailors and Value Added Resellers Outsourcing Companies Healthcare IT Solutions Developers Universities and Business Schools. © Coherent market Insights. All Rights Reserved KEY STATS RESEARCH SOLUTIONS 100+ FEASIBILITY STUDIES Insights Published Per Year GLOBAL REPORTS 150+ Consulting Projects Till Date COUNTRY ANALYSIS CONSULT PROJECTS 125+ Clients Worldwide Per Year 110+ SURVEY RESEARCH EXCEL FORECAST DATABASE CUSTOMIZED SOLUTIONS COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: [email protected] For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights [email protected] +1-206-701-6702 © Coherent market Insights. All Rights Reserved
The drugs which are developed for treatment of rare diseases and conditions are referred to as orphan drugs. The rare diseases such as Tourette syndrome, Huntington’s disease, muscular dystrophy, myoclonus, and ALS (Lou Gehrig’s disease) are some of those diseases for treatment of which adequate drugs have not been developed, and hence these diseases are treated by orphan drugs. Orphan drugs are developed by the pharmaceutical companies for public health need, and the sales generated by this drugs are very minimal when compared to normal drugs. The orphan diseases manifest in patient populations representing 6-8% of the global population. Symptoms of some orphan diseases may appear at birth or in childhood including cystic fibrosis, infantile spinal muscular atrophy, familial adenomatous polyposis (FAP), and some others. Request to download and view Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/500
© Copyright 2024 Paperzz
